Induction of antitumor immunity using bone marrow-generated dendritic cells

Area of Science:

• Immunology
• Cancer Research
• Cell Biology

Background:

• Bone marrow-derived dendritic cells (DC) are known to induce CD8+ cytotoxic T lymphocyte (CTL) responses when pulsed with class I-restricted peptides.
• The potential of these DC to induce broader antitumor immunity remained to be fully elucidated.

Purpose of the Study:

• To investigate the capacity of bone marrow-generated DC to induce protective antitumor immunity.
• To compare the efficacy of DC-based immunization with other immunization strategies.

Main Methods:

• Immunization of mice with DC pulsed with ovalbumin (OVA) peptide.
• Challenging immunized mice with OVA-expressing tumor cells (E.G7-OVA).
• Assessing the induction of CTL and antitumor immunity, and correlating it with MHC molecule expression and T cell involvement.

Main Results:

• A single immunization with OVA peptide-pulsed DC elicited significant protective antitumor immunity against E.G7-OVA tumor challenge.
• Peptide-pulsed DC were more effective than irradiated tumor cells, peptide-pulsed RMA-S cells, or free OVA peptide with adjuvant.
• Addition of OVA protein to early bone marrow cultures enhanced CTL and antitumor immunity but was less effective than peptide-pulsed DC.
• Induction of immunity correlated with syngeneic MHC class II expression on DC and required CD4+ T cells.

Conclusions:

• Bone marrow-derived DC pulsed with class I-restricted peptides can effectively induce protective antitumor immunity.
• The process involves CD4+ T cell activation, suggesting a requirement for MHC class II-restricted epitope presentation.
• These findings have significant implications for the development of DC-based peptide immunotherapy strategies.